Spyryx Biosciences names chief medical officer
Dr. Wheeler joins Spyryx from Sunovion Pharmaceuticals, where he was global head of clinical development, respiratory medicine and biotherapeutics, responsible for all clinical development activities and supporting a portfolio of approved products across multiple therapeutic areas.
Prior to Sunovion, Dr. Wheeler was senior director, clinical research at Cubist Pharmaceuticals, leading the clinical research function for development programs in infectious disease and cardiovascular surgery, in addition to ongoing clinical expansion of a marketed product and business development activities.
Dr. Wheeler’s earlier clinical development experience included positions in both the US and Europe as vice president, medical affairs at Avant Immunotherapeutics; senior director roles in clinical development and clinical operations for Astra USA; world-wide director, respiratory medicine at Hoffmann-La Roche, and clinical research physician (respiratory) for Glaxo Group Research Ltd.
Dr. Wheeler earned his MD from the Royal London Hospital Medical College and his MFPM from the Royal College of Physicians.
He is a member of the American Thoracic Society and former vice president of the American Academy of Pharmaceutical Physicians. ■
LATEST MOVES FROM North Carolina
- Jeld-Wen Holding appoints William Banholzer to board
- QuintilesIMS appoints Colleen Goggins to board
- G1 Therapeutics appoints Sir Andrew Witty to board
- Select Bancorp promotes Lynn H. Johnson to COO
- Extended Stay America appoints Jodie W. McLean as independent director
More inside POST